Allos Therapeutics, Inc. (ALTH) Shareholder Alert: Bernstein Liebhard LLP Announces Investigation of Acquisition By Spectrum Pharmaceuticals
April 5, 2012
Under the terms of the agreement, Allos shareholders will receive $1.82 in cash plus one Contingent Value Right (CVR) for each share they own. This CVR entitles Allos shareholders to an additional payment of $0.11 per share in cash if certain European regulatory approval and commercialization milestones for FOLOTYN® are achieved. The investigation is focused on the potential unfairness of the price to Allos shareholders and the process by which the Allos Board of Directors considered and approved the transaction.
Bernstein Liehhard has pursued hundreds of securities, consumer and shareholder rights cases and recovered over $3 billion for its clients. It has been named to The National Law Journal’s “Plaintiffs’ Hot List” in each of the last nine years.